Compass Therapeutics (CMPX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Compass Therapeutics (CMPX) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.37 of bullish evidence against -0.35 bearish.

Compass Therapeutics last closed at $0.96, +11.63% on the session.

Against the IVW growth benchmark the position is +10.71% over the forecast window.

The read is built from 13 underlying insights — 2 bullish and 11 bearish.

Agreement across those insights is 85%.

Compass Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Compass Therapeutics in the 21st percentile on return on equity, where 100 is best.

Compass Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $154.28M.

StockMap tracks Compass Therapeutics as the 240th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Compass Therapeutics ranks 221st of 344 in the group, against a group median of -0.21.